董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Gregg Honigblum | 男 | Chief Investment Officer and Director | 63 | 97.30万美元 | 24.44 | 2026-10-30 |
| Mark Anderson | 男 | Director | 62 | 15.72万美元 | 4.80 | 2026-10-30 |
| Robert Mitchell | 男 | Director | 63 | 15.72万美元 | 3.00 | 2026-10-30 |
| Chris Lyons | 男 | Director | 56 | 15.72万美元 | 3.83 | 2026-10-30 |
| Jay M. Moyes | 男 | Director | 72 | 16.69万美元 | 3.40 | 2026-10-30 |
| Eric K. Olson | 男 | CEO and Chairman of the Board and Director | 62 | 105.40万美元 | 11.20 | 2026-10-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Gregg Honigblum | 男 | Chief Investment Officer and Director | 63 | 97.30万美元 | 24.44 | 2026-10-30 |
| Kevin Trask | 男 | Chief Financial Officer | 41 | 56.25万美元 | 6.60 | 2026-10-30 |
| Ryan Elmore | 男 | President | 51 | 未披露 | 3.60 | 2026-10-30 |
| Eric K. Olson | 男 | CEO and Chairman of the Board and Director | 62 | 105.40万美元 | 11.20 | 2026-10-30 |
董事简历
中英对照 | 中文 | 英文- Gregg Honigblum
-
Gregg Honigblum，在被任命为首席战略官之前，从2023年12月到2024年11月，Honigblum先生担任FNEX Capital，LLC的董事总经理，该公司是私人证券交易和投资银行业务的全球领导者。从2021年6月至2023年12月，Honigblum先生担任Westlake Securities的董事总经理，Westlake Securities是一家专注于为中间市场公司提供增长、并购和融资服务的投资银行公司。从2016年8月到2023年12月，Honigblum先生是HealthGrowth Capital，LLC的联合创始人和董事，专门提供资本、战略咨询服务，以及与大型批发药品分销商的集团采购组织平台。他在得克萨斯大学奥斯汀分校获得经济学文学学士学位。Honigblum先生持有Series 7、24和63证券牌照。
Gregg Honigblum has served as the Company's Chief Investment Officer since May 2025. Prior to serving as the Company's Chief Investment Officer, Mr. Honigblum served as the Company's Chief Strategy Officer from November 2024 to May 2025. From December 2023 to November 2024, Mr. Honigblum served as a Managing Director for FNEX Capital, LLC, a global leader in Private Securities transaction and investment banking. From June 2021 to December 2023 Mr. Honigblum served as a Managing Director for stlake Securities, an investment banking firm focused on growth, merger and acquisitions, and capital raising services for middle market companies. From August 2016 to December 2023 Mr. Honigblum was a co founder and Director for HealthGrowth Capital, LLC specializing in providing capital, strategic advisory services, and a Group Purchasing Organization Platform with large wholesale pharmaceutical distributors. He earned a Bachelor of Arts degree in Economics from the University of Texas at Atin. Mr. Honigblum holds Series 7, 24, and 63 securities licenses. - Gregg Honigblum，在被任命为首席战略官之前，从2023年12月到2024年11月，Honigblum先生担任FNEX Capital，LLC的董事总经理，该公司是私人证券交易和投资银行业务的全球领导者。从2021年6月至2023年12月，Honigblum先生担任Westlake Securities的董事总经理，Westlake Securities是一家专注于为中间市场公司提供增长、并购和融资服务的投资银行公司。从2016年8月到2023年12月，Honigblum先生是HealthGrowth Capital，LLC的联合创始人和董事，专门提供资本、战略咨询服务，以及与大型批发药品分销商的集团采购组织平台。他在得克萨斯大学奥斯汀分校获得经济学文学学士学位。Honigblum先生持有Series 7、24和63证券牌照。
- Gregg Honigblum has served as the Company's Chief Investment Officer since May 2025. Prior to serving as the Company's Chief Investment Officer, Mr. Honigblum served as the Company's Chief Strategy Officer from November 2024 to May 2025. From December 2023 to November 2024, Mr. Honigblum served as a Managing Director for FNEX Capital, LLC, a global leader in Private Securities transaction and investment banking. From June 2021 to December 2023 Mr. Honigblum served as a Managing Director for stlake Securities, an investment banking firm focused on growth, merger and acquisitions, and capital raising services for middle market companies. From August 2016 to December 2023 Mr. Honigblum was a co founder and Director for HealthGrowth Capital, LLC specializing in providing capital, strategic advisory services, and a Group Purchasing Organization Platform with large wholesale pharmaceutical distributors. He earned a Bachelor of Arts degree in Economics from the University of Texas at Atin. Mr. Honigblum holds Series 7, 24, and 63 securities licenses.
- Mark Anderson
-
Mark Anderson,2022年5月至今，安德森先生担任医疗器械行业顾问。从1991年6月到2022年4月，Anderson先生在公立医疗器械公司波士顿科学担任过多个职务，包括区域经理、区域副总裁和销售总监。安德森先生是一位经验丰富的高管，在医疗设备行业拥有超过35年的经验。他在波士顿科学的经验跨越了心脏病学、守望者、内窥镜和公司合同四个部门。此外，他还为波士顿科学（HCA健康护理）管理了# 1的客户近9年。安德森先生因建立高绩效团队、拓展全球市场以及以强大的商业和临床重点扩展业务而受到认可。安德森先生拥有得克萨斯大学奥斯汀分校金融学工商管理硕士学位。
Mark Anderson was appointed to board of directors in April 2025. Since May 2022, Mr. Anderson has served as a consultant in the medical device industry. From June 1991 to April 2022, Mr. Anderson served in vario roles with Boston Scientific, a public medical device company, including Regional Manager, Area Vice President and Sales Director. Mr. Anderson is a seasoned executive with over 35 years in the medical device industry. His experience at Boston Scientific crossed f divisions Cardiology, Watchman, Endoscopy, and Corporate Contracts. Additionally, he managed the #1 ctomer for Boston Scientific (HCA Healthcare) for nearly 9 years. Mr. Anderson is recognized for building high performing teams, expanding global markets, and scaling binesses with a strong commercial and clinical foc. Mr. Anderson holds a BBA, Finance from The University of Texas at Atin. Mr. Anderson was nominated to serve as a director becae his extensive background and experience in the context of the medical device industry enable him to make significant contributions to the Board. - Mark Anderson,2022年5月至今，安德森先生担任医疗器械行业顾问。从1991年6月到2022年4月，Anderson先生在公立医疗器械公司波士顿科学担任过多个职务，包括区域经理、区域副总裁和销售总监。安德森先生是一位经验丰富的高管，在医疗设备行业拥有超过35年的经验。他在波士顿科学的经验跨越了心脏病学、守望者、内窥镜和公司合同四个部门。此外，他还为波士顿科学（HCA健康护理）管理了# 1的客户近9年。安德森先生因建立高绩效团队、拓展全球市场以及以强大的商业和临床重点扩展业务而受到认可。安德森先生拥有得克萨斯大学奥斯汀分校金融学工商管理硕士学位。
- Mark Anderson was appointed to board of directors in April 2025. Since May 2022, Mr. Anderson has served as a consultant in the medical device industry. From June 1991 to April 2022, Mr. Anderson served in vario roles with Boston Scientific, a public medical device company, including Regional Manager, Area Vice President and Sales Director. Mr. Anderson is a seasoned executive with over 35 years in the medical device industry. His experience at Boston Scientific crossed f divisions Cardiology, Watchman, Endoscopy, and Corporate Contracts. Additionally, he managed the #1 ctomer for Boston Scientific (HCA Healthcare) for nearly 9 years. Mr. Anderson is recognized for building high performing teams, expanding global markets, and scaling binesses with a strong commercial and clinical foc. Mr. Anderson holds a BBA, Finance from The University of Texas at Atin. Mr. Anderson was nominated to serve as a director becae his extensive background and experience in the context of the medical device industry enable him to make significant contributions to the Board.
- Robert Mitchell
-
Robert Mitchell，自2018年3月1日起，担任Conavi Medical Corp.的董事会成员，该公司是一家上市（TSX）、商业阶段的医疗设备公司，专注于设计、制造和营销成像技术，以指导常见的微创心血管手术，目前是他们的人力资源和治理委员会主席。自2021年8月以来，Mitchell先生担任Life Seal Vascular Inc的董事会执行主席，该公司是一家私营医疗设备公司，开创了彻底改变血管内介入的解决方案。Mitchell先生自2024年1月起担任NLP Ventures LLC的普通合伙人。自2022年1月起，他还担任FF20 Ventures一家早期风险投资基金的普通合伙人。自2018年3月起，他担任RDM Enterprises，LLC的董事长和创始人。2010年12月至2018年，Mitchell先生担任Endologix, Inc.总裁，该公司是一家上市公司，专注于治疗主动脉紊乱的创新医疗器械的开发、制造和商业化。Mitchell先生自2008年2月起担任Nellix，Inc.的总裁兼首席执行官，直到该公司于2010年12月被恩多勒吉克斯收购。从2006年11月至2008年2月，Mitchell先生担任上市医疗设备公司AngioDynamics，Inc.的执行副总裁兼首席运营官。从2005年到2006年，Mitchell先生担任Millimed Holdings，Inc.的董事长、总裁兼首席执行官，Millimed Holdings，Inc.是一家位于丹麦罗斯基勒的私营医疗设备公司。2004年至2005年，Mitchell先生担任上市公司Align Technology, Inc.的全球销售副总裁。从1987年到2004年，Mitchell先生在一家私营医疗设备公司Cook Incorporated担任过多个职位，包括诊断和介入、血管内、重症监护等多个业务部门的副总裁兼全球销售和营销总监。Mitchell先生拥有犹他大学的学士学位和印第安纳卫斯理大学的工商管理硕士学位。
Robert Mitchell was appointed to board of directors in April 2025. Since March 1, 2018, he has served on the board of directors of Conavi Medical Corp., a public (TSX), commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures and is currently their chairperson of the HR and Governance Committee. Since August 2021, Mr. Mitchell has served as Executive Chairman of the Board of Directors for Life Seal Vascular Inc, a privately held medical device company pioneering solutions to revolutionize endovascular intervention. Mr. Mitchell is a general partner since January 2024 in NLP Ventures LLC. Since January 2022 he has also served as a General Partner in FF20 Ventures, an early stage venture capital fund. Since March 2018 he has served as Chairman and founder of RDM Enterprises, LLC. From December 2010 to 2018, Mr. Mitchell served as President of Endologix, Inc., a public company focused on the development, manufacture, and commercialization of innovative medical devices for the treatment of aortic disorders. Mr. Mitchell served as President and Chief Executive Officer of Nellix, Inc. from February 2008 until its acquisition of by Endologix in December 2010. From November 2006 to February 2008, Mr. Mitchell served as Executive Vice President and Chief Operating Officer of AngioDynamics, Inc., a publicly held medical device company. From 2005 to 2006, Mr. Mitchell served as Chairman, President and Chief Executive Officer of Millimed Holdings, Inc., a privately held medical device company based in Roskilde, Denmark. From 2004 to 2005, Mr. Mitchell served as Vice President of Worldwide Sales for Align Technology, Inc., a publicly held company. From 1987 to 2004, Mr. Mitchell held vario positions with Cook Incorporated, a privately held medical device company, including Vice President and Director, Global Sales and Marketing for vario biness units including diagnostic and interventional, endovascular, critical care. Mr. Mitchell holds a B.S. from the University of Utah and an M.B.A. from Indiana sleyan University. Mr. Mitchell was nominated to serve as a director becae his extensive background and experience in the context of the life sciences industry enable him to make significant contributions to the Board. - Robert Mitchell，自2018年3月1日起，担任Conavi Medical Corp.的董事会成员，该公司是一家上市（TSX）、商业阶段的医疗设备公司，专注于设计、制造和营销成像技术，以指导常见的微创心血管手术，目前是他们的人力资源和治理委员会主席。自2021年8月以来，Mitchell先生担任Life Seal Vascular Inc的董事会执行主席，该公司是一家私营医疗设备公司，开创了彻底改变血管内介入的解决方案。Mitchell先生自2024年1月起担任NLP Ventures LLC的普通合伙人。自2022年1月起，他还担任FF20 Ventures一家早期风险投资基金的普通合伙人。自2018年3月起，他担任RDM Enterprises，LLC的董事长和创始人。2010年12月至2018年，Mitchell先生担任Endologix, Inc.总裁，该公司是一家上市公司，专注于治疗主动脉紊乱的创新医疗器械的开发、制造和商业化。Mitchell先生自2008年2月起担任Nellix，Inc.的总裁兼首席执行官，直到该公司于2010年12月被恩多勒吉克斯收购。从2006年11月至2008年2月，Mitchell先生担任上市医疗设备公司AngioDynamics，Inc.的执行副总裁兼首席运营官。从2005年到2006年，Mitchell先生担任Millimed Holdings，Inc.的董事长、总裁兼首席执行官，Millimed Holdings，Inc.是一家位于丹麦罗斯基勒的私营医疗设备公司。2004年至2005年，Mitchell先生担任上市公司Align Technology, Inc.的全球销售副总裁。从1987年到2004年，Mitchell先生在一家私营医疗设备公司Cook Incorporated担任过多个职位，包括诊断和介入、血管内、重症监护等多个业务部门的副总裁兼全球销售和营销总监。Mitchell先生拥有犹他大学的学士学位和印第安纳卫斯理大学的工商管理硕士学位。
- Robert Mitchell was appointed to board of directors in April 2025. Since March 1, 2018, he has served on the board of directors of Conavi Medical Corp., a public (TSX), commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures and is currently their chairperson of the HR and Governance Committee. Since August 2021, Mr. Mitchell has served as Executive Chairman of the Board of Directors for Life Seal Vascular Inc, a privately held medical device company pioneering solutions to revolutionize endovascular intervention. Mr. Mitchell is a general partner since January 2024 in NLP Ventures LLC. Since January 2022 he has also served as a General Partner in FF20 Ventures, an early stage venture capital fund. Since March 2018 he has served as Chairman and founder of RDM Enterprises, LLC. From December 2010 to 2018, Mr. Mitchell served as President of Endologix, Inc., a public company focused on the development, manufacture, and commercialization of innovative medical devices for the treatment of aortic disorders. Mr. Mitchell served as President and Chief Executive Officer of Nellix, Inc. from February 2008 until its acquisition of by Endologix in December 2010. From November 2006 to February 2008, Mr. Mitchell served as Executive Vice President and Chief Operating Officer of AngioDynamics, Inc., a publicly held medical device company. From 2005 to 2006, Mr. Mitchell served as Chairman, President and Chief Executive Officer of Millimed Holdings, Inc., a privately held medical device company based in Roskilde, Denmark. From 2004 to 2005, Mr. Mitchell served as Vice President of Worldwide Sales for Align Technology, Inc., a publicly held company. From 1987 to 2004, Mr. Mitchell held vario positions with Cook Incorporated, a privately held medical device company, including Vice President and Director, Global Sales and Marketing for vario biness units including diagnostic and interventional, endovascular, critical care. Mr. Mitchell holds a B.S. from the University of Utah and an M.B.A. from Indiana sleyan University. Mr. Mitchell was nominated to serve as a director becae his extensive background and experience in the context of the life sciences industry enable him to make significant contributions to the Board.
- Chris Lyons
-
Chris Lyons，自2024年1月以来，Lyons先生一直担任BiotechExec的合伙人，BiotechExec是一家为医疗设备、生物技术、诊断和数字健康公司提供高管管理服务和部分高管安置的供应商。此外，自2018年1月以来，莱昂斯先生一直担任Southern Metrics Consulting的首席执行官，在那里他为新兴的医疗技术公司提供商业化和成功退出方面的建议。Lyons先生曾任职于美敦力 Spine and Biologics，从2005年2月至2018年1月担任多个职务，包括10年全球业务发展总监，担任国际生物营销总监，以及高级产品经理– International Biologics。在加入美敦力之前，Lyons先生曾在施乐辉工作了16年，担任过多种职务，包括临床疗法销售代表、集团经理骨科导航和集团产品经理。Lyons先生拥有孟菲斯大学福格曼商业与经济学院市场营销与销售工商管理硕士学位。
Chris Lyons has served on board of directors since April 2025. Since January 2024, Mr. Lyons has served as a partner with BiotechExec, a provider of executive management services and fractional executive placement for medical device, biotech, diagnostics and digital health companies. Additionally, since January 2018, Mr. Lyons has served as the chief executive officer for Southern Metrics Consulting where he advises emerging medtech companies on commercialization and successful exits. Mr. Lyons worked for Medtronic Spine and Biologics, from February 2005 to January 2018 in vario roles, including Director Global Biness Development for 10 years, as Director of International Biologic Marketing, and Senior Product Manager – International Biologics. Prior to joining Medtronic, Mr. Lyons worked for Smith & Nephew for 16 years in vario roles including Clinical Therapies Sales Representative, Group Manager Orthopedic Navigation and Group Product Manager. Mr. Lyons holds a BBA, Marketing & Sales from Fogelman College of Biness & Economics, University of Memphis. Mr. Lyons was nominated to serve as a director becae his extensive background and experience in the context of the medical device industry enable him to make significant contributions to the Board. - Chris Lyons，自2024年1月以来，Lyons先生一直担任BiotechExec的合伙人，BiotechExec是一家为医疗设备、生物技术、诊断和数字健康公司提供高管管理服务和部分高管安置的供应商。此外，自2018年1月以来，莱昂斯先生一直担任Southern Metrics Consulting的首席执行官，在那里他为新兴的医疗技术公司提供商业化和成功退出方面的建议。Lyons先生曾任职于美敦力 Spine and Biologics，从2005年2月至2018年1月担任多个职务，包括10年全球业务发展总监，担任国际生物营销总监，以及高级产品经理– International Biologics。在加入美敦力之前，Lyons先生曾在施乐辉工作了16年，担任过多种职务，包括临床疗法销售代表、集团经理骨科导航和集团产品经理。Lyons先生拥有孟菲斯大学福格曼商业与经济学院市场营销与销售工商管理硕士学位。
- Chris Lyons has served on board of directors since April 2025. Since January 2024, Mr. Lyons has served as a partner with BiotechExec, a provider of executive management services and fractional executive placement for medical device, biotech, diagnostics and digital health companies. Additionally, since January 2018, Mr. Lyons has served as the chief executive officer for Southern Metrics Consulting where he advises emerging medtech companies on commercialization and successful exits. Mr. Lyons worked for Medtronic Spine and Biologics, from February 2005 to January 2018 in vario roles, including Director Global Biness Development for 10 years, as Director of International Biologic Marketing, and Senior Product Manager – International Biologics. Prior to joining Medtronic, Mr. Lyons worked for Smith & Nephew for 16 years in vario roles including Clinical Therapies Sales Representative, Group Manager Orthopedic Navigation and Group Product Manager. Mr. Lyons holds a BBA, Marketing & Sales from Fogelman College of Biness & Economics, University of Memphis. Mr. Lyons was nominated to serve as a director becae his extensive background and experience in the context of the medical device industry enable him to make significant contributions to the Board.
- Jay M. Moyes
-
Jay M. Moyes，他还担任Puma Biotechnology， Inc.（一家公共生物制药公司，专注于创新产品的开发和商业化，以加强癌症治疗）的董事会成员。Moyes先生自2011年1月起担任Biocardia， Inc.（公共心血管再生医学公司）的董事会成员。从2020年3月到2023年6月，Moyes先生担任Sera Prognostics， Inc.（一家公共商业阶段的生物技术公司，专注于通过创新的生物标志物方法改善孕产妇和新生儿健康）的首席财务官。Moyes先生此前曾担任Achieve Life Sciences， Inc.（上市专业制药公司）的董事会成员（从2017年8月到2023年5月）；Predictive Technology Group, Inc.，一家公共分子诊断和再生医学公司，从2019年2月至2019年12月；Osiris Therapeutics, Inc.，一家公共生物外科公司，从2006年5月到2017年12月；2012年11月至2014年8月，他担任美国公司（现SINTX Technologies， Inc.），一家公共骨科植入物公司。2013年10月至2014年8月，他担任美国首席财务官。从2008年5月到2009年7月，Moyes先生担任XDx（现为CareDx）， Inc.（一家私营分子诊断公司）的首席财务官。在此之前，他从1996年6月到2007年11月担任Myriad Genetics， Inc.（公共医疗保健诊断公司）的首席财务官，并从1993年7月到2005年7月担任财务副总裁。从1991年到1993年，Moyes先生担任Genmark， Inc.（一家私人控股的基因公司）的财务副总裁和首席财务官。1979年至1991年，他在毕马威会计师事务所担任多个职位，最近担任高级经理。他持有Utah大学的工商管理硕士学位，Weber State大学的经济学学士学位，并曾是一名注册会计师。他也曾担任the Utah Life Science Association的董事会成员（从1999年到2006年）。
Jay M. Moyes Jay M. Moyes has served on board of directors since 2011. He has served on the board of directors of Puma Biotechnologies (NYSE: PBYI) since April 2012, and on the board of directors of Achieve Life Sciences from 2018 to the present and he served on the board of directors and Chairman of the Audit Committee of Osiris Therapeutics (NASDAQ: OSIR), a biosurgical company, from May 2006 until December 2017. He also served as a member of the board of directors and Chairman of the Audit Committee of Integrated Diagnostics, a privately held molecular diagnostics company, from 2011 to 2016. From 2012 to 2014, Mr. Moyes served as a member of the board of directors of Amedica Corporation, a publicly traded orthopedics company, and as Chief Financial Officer from 2013 to 2014. Mr. Moyes was the Chief Financial Officer of Sera Prognostics, Inc. (NASDAQ: SERA), a women's health diagnostics company, from March 2020 to June 2023. From 2008 to 2009, Mr. Moyes served as Chief Financial Officer of CareDx, a publicly traded molecular diagnostics company. Prior to that, he served as Chief Financial Officer of Myriad Genetics, Inc., a publicly held healthcare diagnostics company, from June 1996 until November 2007, and as Vice President of Finance from July 1993 until July 2005. From 1991 to 1993, Mr. Moyes served as Vice President of Finance and Chief Financial Officer of Genmark, a privately held genetics company. Mr. Moyes held vario positions with the accounting firm of KPMG from 1979 to 1991. He also served as a member of the Board of Trtees of the Utah Life Science Association from 1999 to 2006. Mr. Moyes holds a Master of Biness Administration from the University of Utah, a Bachelor of Arts in economics from ber State University and is formerly a Certified Public Accountant. - Jay M. Moyes，他还担任Puma Biotechnology， Inc.（一家公共生物制药公司，专注于创新产品的开发和商业化，以加强癌症治疗）的董事会成员。Moyes先生自2011年1月起担任Biocardia， Inc.（公共心血管再生医学公司）的董事会成员。从2020年3月到2023年6月，Moyes先生担任Sera Prognostics， Inc.（一家公共商业阶段的生物技术公司，专注于通过创新的生物标志物方法改善孕产妇和新生儿健康）的首席财务官。Moyes先生此前曾担任Achieve Life Sciences， Inc.（上市专业制药公司）的董事会成员（从2017年8月到2023年5月）；Predictive Technology Group, Inc.，一家公共分子诊断和再生医学公司，从2019年2月至2019年12月；Osiris Therapeutics, Inc.，一家公共生物外科公司，从2006年5月到2017年12月；2012年11月至2014年8月，他担任美国公司（现SINTX Technologies， Inc.），一家公共骨科植入物公司。2013年10月至2014年8月，他担任美国首席财务官。从2008年5月到2009年7月，Moyes先生担任XDx（现为CareDx）， Inc.（一家私营分子诊断公司）的首席财务官。在此之前，他从1996年6月到2007年11月担任Myriad Genetics， Inc.（公共医疗保健诊断公司）的首席财务官，并从1993年7月到2005年7月担任财务副总裁。从1991年到1993年，Moyes先生担任Genmark， Inc.（一家私人控股的基因公司）的财务副总裁和首席财务官。1979年至1991年，他在毕马威会计师事务所担任多个职位，最近担任高级经理。他持有Utah大学的工商管理硕士学位，Weber State大学的经济学学士学位，并曾是一名注册会计师。他也曾担任the Utah Life Science Association的董事会成员（从1999年到2006年）。
- Jay M. Moyes Jay M. Moyes has served on board of directors since 2011. He has served on the board of directors of Puma Biotechnologies (NYSE: PBYI) since April 2012, and on the board of directors of Achieve Life Sciences from 2018 to the present and he served on the board of directors and Chairman of the Audit Committee of Osiris Therapeutics (NASDAQ: OSIR), a biosurgical company, from May 2006 until December 2017. He also served as a member of the board of directors and Chairman of the Audit Committee of Integrated Diagnostics, a privately held molecular diagnostics company, from 2011 to 2016. From 2012 to 2014, Mr. Moyes served as a member of the board of directors of Amedica Corporation, a publicly traded orthopedics company, and as Chief Financial Officer from 2013 to 2014. Mr. Moyes was the Chief Financial Officer of Sera Prognostics, Inc. (NASDAQ: SERA), a women's health diagnostics company, from March 2020 to June 2023. From 2008 to 2009, Mr. Moyes served as Chief Financial Officer of CareDx, a publicly traded molecular diagnostics company. Prior to that, he served as Chief Financial Officer of Myriad Genetics, Inc., a publicly held healthcare diagnostics company, from June 1996 until November 2007, and as Vice President of Finance from July 1993 until July 2005. From 1991 to 1993, Mr. Moyes served as Vice President of Finance and Chief Financial Officer of Genmark, a privately held genetics company. Mr. Moyes held vario positions with the accounting firm of KPMG from 1979 to 1991. He also served as a member of the Board of Trtees of the Utah Life Science Association from 1999 to 2006. Mr. Moyes holds a Master of Biness Administration from the University of Utah, a Bachelor of Arts in economics from ber State University and is formerly a Certified Public Accountant.
- Eric K. Olson
-
Eric K. Olson，自2024年8月起担任公司首席执行官兼总裁。在被任命为首席执行官兼总裁之前，2022年6月至2024年8月，奥尔森先生担任Foresite Innovations，LLC的创始人、首席执行官和董事会成员，该公司是一家私营的医疗保健创新和发展控股公司。2016年1月至2022年6月，奥尔森先生是Predictive Biotech，Inc.的创始人、总裁、首席执行官和董事会成员，该公司开发了首个源自围产期组织的人类干细胞和组织产品（HCT/P）。在加入Predictive Biotech之前，Olson先生于2014年12月至2016年1月担任基于Cupertino的骨骼动力学的总裁兼首席执行官。这家Colson & Associates公司开发并商业化了用于骨科和脊柱应用的合成骨替代产品。2012年2月至2014年9月，Olson先生担任SINTX Technologies（前身为Amedica Corporation）的首席执行官兼总裁和董事会成员。Olson先生的职业生涯始于总部在伦敦的施乐辉，曾在强生、美敦力和Wright医疗担任高级销售和营销领导职务。他在犹他大学获得行为科学和健康管理理学学士学位，并在同一机构完成了硕士级别的医院管理实习课程。
Eric K. Olson was appointed to the board of directors in November 2024 and has served as Chief Executive Officer since August 1, 2024. Prior to being appointed as Chief Executive Officer, from June 2022 to August 2024, Mr. Olson served as Founder, Chief Executive Officer and Board Member of Foresite Innovations, LLC, a private healthcare innovation and development holding company. From January 2016 to June 2022, Mr. Olson was the founder, President, Chief Executive Officer and Board Member of Predictive Biotech, Inc., which developed the first human stem cell and tissue product (HCT/P) derived from the perinatal tissue. Prior to joining Predictive Biotech, Mr. Olson was the President and Chief Executive Officer for Cupertino based Skeletal Kinetics from December 2014 to January 2016. This Colson & Associates company developed and commercialized synthetic bone substitute products for Orthopedic and Spinal applications. From February 2012 to September 2014, Mr. Olson served as Chief Executive Officer and President and a member of the board of directors of SINTX Technologies (formerly Amedica Corporation). Mr. Olson began his career with London based Smith & Nephew and has worked in Senior Sales and Marketing leadership roles with Johnson & Johnson, Medtronic and Wright Medical. He earned Bachelor of Science Degrees in Behavioral Science and Health Administration from The University of Utah and completed a Master's level Hospital Administration Internship Program at the same institution. - Eric K. Olson，自2024年8月起担任公司首席执行官兼总裁。在被任命为首席执行官兼总裁之前，2022年6月至2024年8月，奥尔森先生担任Foresite Innovations，LLC的创始人、首席执行官和董事会成员，该公司是一家私营的医疗保健创新和发展控股公司。2016年1月至2022年6月，奥尔森先生是Predictive Biotech，Inc.的创始人、总裁、首席执行官和董事会成员，该公司开发了首个源自围产期组织的人类干细胞和组织产品（HCT/P）。在加入Predictive Biotech之前，Olson先生于2014年12月至2016年1月担任基于Cupertino的骨骼动力学的总裁兼首席执行官。这家Colson & Associates公司开发并商业化了用于骨科和脊柱应用的合成骨替代产品。2012年2月至2014年9月，Olson先生担任SINTX Technologies（前身为Amedica Corporation）的首席执行官兼总裁和董事会成员。Olson先生的职业生涯始于总部在伦敦的施乐辉，曾在强生、美敦力和Wright医疗担任高级销售和营销领导职务。他在犹他大学获得行为科学和健康管理理学学士学位，并在同一机构完成了硕士级别的医院管理实习课程。
- Eric K. Olson was appointed to the board of directors in November 2024 and has served as Chief Executive Officer since August 1, 2024. Prior to being appointed as Chief Executive Officer, from June 2022 to August 2024, Mr. Olson served as Founder, Chief Executive Officer and Board Member of Foresite Innovations, LLC, a private healthcare innovation and development holding company. From January 2016 to June 2022, Mr. Olson was the founder, President, Chief Executive Officer and Board Member of Predictive Biotech, Inc., which developed the first human stem cell and tissue product (HCT/P) derived from the perinatal tissue. Prior to joining Predictive Biotech, Mr. Olson was the President and Chief Executive Officer for Cupertino based Skeletal Kinetics from December 2014 to January 2016. This Colson & Associates company developed and commercialized synthetic bone substitute products for Orthopedic and Spinal applications. From February 2012 to September 2014, Mr. Olson served as Chief Executive Officer and President and a member of the board of directors of SINTX Technologies (formerly Amedica Corporation). Mr. Olson began his career with London based Smith & Nephew and has worked in Senior Sales and Marketing leadership roles with Johnson & Johnson, Medtronic and Wright Medical. He earned Bachelor of Science Degrees in Behavioral Science and Health Administration from The University of Utah and completed a Master's level Hospital Administration Internship Program at the same institution.
高管简历
中英对照 | 中文 | 英文- Gregg Honigblum
Gregg Honigblum，在被任命为首席战略官之前，从2023年12月到2024年11月，Honigblum先生担任FNEX Capital，LLC的董事总经理，该公司是私人证券交易和投资银行业务的全球领导者。从2021年6月至2023年12月，Honigblum先生担任Westlake Securities的董事总经理，Westlake Securities是一家专注于为中间市场公司提供增长、并购和融资服务的投资银行公司。从2016年8月到2023年12月，Honigblum先生是HealthGrowth Capital，LLC的联合创始人和董事，专门提供资本、战略咨询服务，以及与大型批发药品分销商的集团采购组织平台。他在得克萨斯大学奥斯汀分校获得经济学文学学士学位。Honigblum先生持有Series 7、24和63证券牌照。
Gregg Honigblum has served as the Company's Chief Investment Officer since May 2025. Prior to serving as the Company's Chief Investment Officer, Mr. Honigblum served as the Company's Chief Strategy Officer from November 2024 to May 2025. From December 2023 to November 2024, Mr. Honigblum served as a Managing Director for FNEX Capital, LLC, a global leader in Private Securities transaction and investment banking. From June 2021 to December 2023 Mr. Honigblum served as a Managing Director for stlake Securities, an investment banking firm focused on growth, merger and acquisitions, and capital raising services for middle market companies. From August 2016 to December 2023 Mr. Honigblum was a co founder and Director for HealthGrowth Capital, LLC specializing in providing capital, strategic advisory services, and a Group Purchasing Organization Platform with large wholesale pharmaceutical distributors. He earned a Bachelor of Arts degree in Economics from the University of Texas at Atin. Mr. Honigblum holds Series 7, 24, and 63 securities licenses.- Gregg Honigblum，在被任命为首席战略官之前，从2023年12月到2024年11月，Honigblum先生担任FNEX Capital，LLC的董事总经理，该公司是私人证券交易和投资银行业务的全球领导者。从2021年6月至2023年12月，Honigblum先生担任Westlake Securities的董事总经理，Westlake Securities是一家专注于为中间市场公司提供增长、并购和融资服务的投资银行公司。从2016年8月到2023年12月，Honigblum先生是HealthGrowth Capital，LLC的联合创始人和董事，专门提供资本、战略咨询服务，以及与大型批发药品分销商的集团采购组织平台。他在得克萨斯大学奥斯汀分校获得经济学文学学士学位。Honigblum先生持有Series 7、24和63证券牌照。
- Gregg Honigblum has served as the Company's Chief Investment Officer since May 2025. Prior to serving as the Company's Chief Investment Officer, Mr. Honigblum served as the Company's Chief Strategy Officer from November 2024 to May 2025. From December 2023 to November 2024, Mr. Honigblum served as a Managing Director for FNEX Capital, LLC, a global leader in Private Securities transaction and investment banking. From June 2021 to December 2023 Mr. Honigblum served as a Managing Director for stlake Securities, an investment banking firm focused on growth, merger and acquisitions, and capital raising services for middle market companies. From August 2016 to December 2023 Mr. Honigblum was a co founder and Director for HealthGrowth Capital, LLC specializing in providing capital, strategic advisory services, and a Group Purchasing Organization Platform with large wholesale pharmaceutical distributors. He earned a Bachelor of Arts degree in Economics from the University of Texas at Atin. Mr. Honigblum holds Series 7, 24, and 63 securities licenses.
- Kevin Trask
Kevin Trask，于2025年5月至2025年9月担任公司公司控制人。2024年5月至2025年5月，在全球上市公司USANA Health Sciences，Inc.担任公司财务总监。2022年10月至2024年5月，Trask先生在一家早期私营消费品公司担任财务和会计主管。从2021年6月至2022年10月，Trask先生担任上市公司Quotient Technologies，Inc的会计总监。在加入Quotient之前，Trask先生曾在全球上市公司担任多个渐进式会计和财务管理职位。他的职业生涯始于公共会计，为大大小小的私营和上市公司提供鉴证服务。Trask先生拥有加州州立理工大学会计学学士学位，是一名积极获得许可的注册会计师。
Kevin Trask has served as the Company's Chief Financial Officer since September 2025. Prior to being appointed as the Company's Chief Financial Officer, Mr. Trask served as the Company's Corporate Controller from May 2025 to September 2025. From May 2024 to May 2025, he served as Corporate Controller at ANA Health Sciences, Inc., a global publicly traded company. From October 2022 to May 2024, Mr. Trask served as the Head of Finance and Accounting at an early stage private consumer goods company. From June 2021 to October 2022, Mr. Trask served as the Director of Accounting at Quotient Technologies, Inc, a publicly traded company. Prior to Quotient, Mr. Trask held multiple, progressive accounting and finance management positions at global publicly traded companies. He began his career in public accounting, providing assurance services to both large and small private and public companies. Mr. Trask holds a B.S. in Accounting from California State Polytechnic University and is an actively licensed CPA.- Kevin Trask，于2025年5月至2025年9月担任公司公司控制人。2024年5月至2025年5月，在全球上市公司USANA Health Sciences，Inc.担任公司财务总监。2022年10月至2024年5月，Trask先生在一家早期私营消费品公司担任财务和会计主管。从2021年6月至2022年10月，Trask先生担任上市公司Quotient Technologies，Inc的会计总监。在加入Quotient之前，Trask先生曾在全球上市公司担任多个渐进式会计和财务管理职位。他的职业生涯始于公共会计，为大大小小的私营和上市公司提供鉴证服务。Trask先生拥有加州州立理工大学会计学学士学位，是一名积极获得许可的注册会计师。
- Kevin Trask has served as the Company's Chief Financial Officer since September 2025. Prior to being appointed as the Company's Chief Financial Officer, Mr. Trask served as the Company's Corporate Controller from May 2025 to September 2025. From May 2024 to May 2025, he served as Corporate Controller at ANA Health Sciences, Inc., a global publicly traded company. From October 2022 to May 2024, Mr. Trask served as the Head of Finance and Accounting at an early stage private consumer goods company. From June 2021 to October 2022, Mr. Trask served as the Director of Accounting at Quotient Technologies, Inc, a publicly traded company. Prior to Quotient, Mr. Trask held multiple, progressive accounting and finance management positions at global publicly traded companies. He began his career in public accounting, providing assurance services to both large and small private and public companies. Mr. Trask holds a B.S. in Accounting from California State Polytechnic University and is an actively licensed CPA.
- Ryan Elmore
Ryan Elmore自2026年3月16日起担任SINTX Technologies公司总裁。Elmore先生向首席执行官报告，负责执行公司的BINEY和运营战略，包括创新、商业化、BINEY开发以及公司专有的可植入级氮化硅生物材料平台SINERGY的全球扩张。在加入SINTX之前，Elmore先生曾在医疗设备应用领域高性能生物材料和聚合物ed的全球制造商Victrex plc的一个部门Invibio担任多个领导职务。最近，从2021年9月到2026年3月，他担任Core Biness总监，负责领导威格斯生物材料Biness在三个战略领域的工作，包括金属骨骼、心血管和药品市场。2010年10月至2021年11月，Elmore先生担任Invibio全球销售主管，负责全球各大洲的国际商业战略、渠道管理、合同管理和销售执行，包括促进亚洲高增长市场。Elmore先生拥有学士学位。通过南佛罗里达大学生物医学工程认证，在机械工程方面具有亚专业。
Ryan Elmore has served as President of SINTX Technologies, Inc. since March 16, 2026. Mr. Elmore reports to the Chief Executive Officer and is responsible for execution of the Company's biness and operational strategy, including innovation, commercialization, biness development, and global expansion of SiNERGY, the Company's proprietary implantable grade silicon nitride biomaterial platform. Prior to joining SINTX, Mr. Elmore served in vario leadership roles at Invibio, a division of Victrex plc, a global manufacturer of high performance biomaterials and polymers ed in medical device applications. Most recently, from September 2021 to March 2026, he served as Core Biness Director, where he was responsible for leadership of the Victrex Biomaterials biness across three strategic segments including Mculoskeletal, Cardiovascular, and Pharmaceutical markets. From October 2010 to November 2021, Mr. Elmore served as Invibio Global Head of Sales, with responsibility for international commercial strategy, channel management, contracts administration and sales execution across all continents including facilitation of high growth markets in Asia. Mr. Elmore holds a B.S. In Mechanical Engineering with sub specialization through certification in Biomedical Engineering from the University of South Florida.- Ryan Elmore自2026年3月16日起担任SINTX Technologies公司总裁。Elmore先生向首席执行官报告，负责执行公司的BINEY和运营战略，包括创新、商业化、BINEY开发以及公司专有的可植入级氮化硅生物材料平台SINERGY的全球扩张。在加入SINTX之前，Elmore先生曾在医疗设备应用领域高性能生物材料和聚合物ed的全球制造商Victrex plc的一个部门Invibio担任多个领导职务。最近，从2021年9月到2026年3月，他担任Core Biness总监，负责领导威格斯生物材料Biness在三个战略领域的工作，包括金属骨骼、心血管和药品市场。2010年10月至2021年11月，Elmore先生担任Invibio全球销售主管，负责全球各大洲的国际商业战略、渠道管理、合同管理和销售执行，包括促进亚洲高增长市场。Elmore先生拥有学士学位。通过南佛罗里达大学生物医学工程认证，在机械工程方面具有亚专业。
- Ryan Elmore has served as President of SINTX Technologies, Inc. since March 16, 2026. Mr. Elmore reports to the Chief Executive Officer and is responsible for execution of the Company's biness and operational strategy, including innovation, commercialization, biness development, and global expansion of SiNERGY, the Company's proprietary implantable grade silicon nitride biomaterial platform. Prior to joining SINTX, Mr. Elmore served in vario leadership roles at Invibio, a division of Victrex plc, a global manufacturer of high performance biomaterials and polymers ed in medical device applications. Most recently, from September 2021 to March 2026, he served as Core Biness Director, where he was responsible for leadership of the Victrex Biomaterials biness across three strategic segments including Mculoskeletal, Cardiovascular, and Pharmaceutical markets. From October 2010 to November 2021, Mr. Elmore served as Invibio Global Head of Sales, with responsibility for international commercial strategy, channel management, contracts administration and sales execution across all continents including facilitation of high growth markets in Asia. Mr. Elmore holds a B.S. In Mechanical Engineering with sub specialization through certification in Biomedical Engineering from the University of South Florida.
- Eric K. Olson
Eric K. Olson，自2024年8月起担任公司首席执行官兼总裁。在被任命为首席执行官兼总裁之前，2022年6月至2024年8月，奥尔森先生担任Foresite Innovations，LLC的创始人、首席执行官和董事会成员，该公司是一家私营的医疗保健创新和发展控股公司。2016年1月至2022年6月，奥尔森先生是Predictive Biotech，Inc.的创始人、总裁、首席执行官和董事会成员，该公司开发了首个源自围产期组织的人类干细胞和组织产品（HCT/P）。在加入Predictive Biotech之前，Olson先生于2014年12月至2016年1月担任基于Cupertino的骨骼动力学的总裁兼首席执行官。这家Colson & Associates公司开发并商业化了用于骨科和脊柱应用的合成骨替代产品。2012年2月至2014年9月，Olson先生担任SINTX Technologies（前身为Amedica Corporation）的首席执行官兼总裁和董事会成员。Olson先生的职业生涯始于总部在伦敦的施乐辉，曾在强生、美敦力和Wright医疗担任高级销售和营销领导职务。他在犹他大学获得行为科学和健康管理理学学士学位，并在同一机构完成了硕士级别的医院管理实习课程。
Eric K. Olson was appointed to the board of directors in November 2024 and has served as Chief Executive Officer since August 1, 2024. Prior to being appointed as Chief Executive Officer, from June 2022 to August 2024, Mr. Olson served as Founder, Chief Executive Officer and Board Member of Foresite Innovations, LLC, a private healthcare innovation and development holding company. From January 2016 to June 2022, Mr. Olson was the founder, President, Chief Executive Officer and Board Member of Predictive Biotech, Inc., which developed the first human stem cell and tissue product (HCT/P) derived from the perinatal tissue. Prior to joining Predictive Biotech, Mr. Olson was the President and Chief Executive Officer for Cupertino based Skeletal Kinetics from December 2014 to January 2016. This Colson & Associates company developed and commercialized synthetic bone substitute products for Orthopedic and Spinal applications. From February 2012 to September 2014, Mr. Olson served as Chief Executive Officer and President and a member of the board of directors of SINTX Technologies (formerly Amedica Corporation). Mr. Olson began his career with London based Smith & Nephew and has worked in Senior Sales and Marketing leadership roles with Johnson & Johnson, Medtronic and Wright Medical. He earned Bachelor of Science Degrees in Behavioral Science and Health Administration from The University of Utah and completed a Master's level Hospital Administration Internship Program at the same institution.- Eric K. Olson，自2024年8月起担任公司首席执行官兼总裁。在被任命为首席执行官兼总裁之前，2022年6月至2024年8月，奥尔森先生担任Foresite Innovations，LLC的创始人、首席执行官和董事会成员，该公司是一家私营的医疗保健创新和发展控股公司。2016年1月至2022年6月，奥尔森先生是Predictive Biotech，Inc.的创始人、总裁、首席执行官和董事会成员，该公司开发了首个源自围产期组织的人类干细胞和组织产品（HCT/P）。在加入Predictive Biotech之前，Olson先生于2014年12月至2016年1月担任基于Cupertino的骨骼动力学的总裁兼首席执行官。这家Colson & Associates公司开发并商业化了用于骨科和脊柱应用的合成骨替代产品。2012年2月至2014年9月，Olson先生担任SINTX Technologies（前身为Amedica Corporation）的首席执行官兼总裁和董事会成员。Olson先生的职业生涯始于总部在伦敦的施乐辉，曾在强生、美敦力和Wright医疗担任高级销售和营销领导职务。他在犹他大学获得行为科学和健康管理理学学士学位，并在同一机构完成了硕士级别的医院管理实习课程。
- Eric K. Olson was appointed to the board of directors in November 2024 and has served as Chief Executive Officer since August 1, 2024. Prior to being appointed as Chief Executive Officer, from June 2022 to August 2024, Mr. Olson served as Founder, Chief Executive Officer and Board Member of Foresite Innovations, LLC, a private healthcare innovation and development holding company. From January 2016 to June 2022, Mr. Olson was the founder, President, Chief Executive Officer and Board Member of Predictive Biotech, Inc., which developed the first human stem cell and tissue product (HCT/P) derived from the perinatal tissue. Prior to joining Predictive Biotech, Mr. Olson was the President and Chief Executive Officer for Cupertino based Skeletal Kinetics from December 2014 to January 2016. This Colson & Associates company developed and commercialized synthetic bone substitute products for Orthopedic and Spinal applications. From February 2012 to September 2014, Mr. Olson served as Chief Executive Officer and President and a member of the board of directors of SINTX Technologies (formerly Amedica Corporation). Mr. Olson began his career with London based Smith & Nephew and has worked in Senior Sales and Marketing leadership roles with Johnson & Johnson, Medtronic and Wright Medical. He earned Bachelor of Science Degrees in Behavioral Science and Health Administration from The University of Utah and completed a Master's level Hospital Administration Internship Program at the same institution.